Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313177 | 0.98 | LMNA (0.50) | LMNASMN1; SMN2TSHRSLC16A3ALDH1A1 | |
| SCHEMBL530537 | 0.89 | SLC16A3 (0.58) | TSHRSLC16A3FOLH1 | |
| SCHEMBL15554730 | 0.89 | SLC16A3 (0.58) | TSHRSLC16A3FOLH1 | |
| SCHEMBL4599890 | 0.87 | FOLH1 (0.56) | LMNATSHRSLC16A3ALDH1A1FOLH1 | |
| SCHEMBL19604258 | 0.86 | TSHR (0.55) | LMNASMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL4703927 | 0.83 | FOLH1 (0.56) | LMNATSHRSLC16A3ALDH1A1KDM4E | |
| SCHEMBL5709997 | 0.81 | LIPG (0.56) | LMNATSHRALDH1A1 | |
| SCHEMBL5164407 | 0.81 | LIPG (0.56) | LMNATSHRALDH1A1 | |
| SCHEMBL11441324 | 0.81 | LIPG (0.56) | LMNATSHRALDH1A1 | |
| SCHEMBL1577630 | 0.81 | LIPG (0.56) | LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | LMNA 3460/4885SMN1; SMN2 4777/4885TSHR 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.